Abstract
Thirty-five years after the 'war on cancer' was declared, the discovery of anticancer drugs remains a highly challenging endeavour. Here, we consider the factors responsible, such as tumour heterogeneity, and suggest strategies to improve the chances of short-term success in the development of novel anticancer drugs.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
Purchase on Springer Link
Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Kola, I. & Landis, J. Can the pharmaceutical industry reduce attrition rates? Nature Rev. Drug Discov. 3, 711–715 (2004).
Roberts, T. G. Jr et al. Trends in the risks and benefits to patients with cancer participating in phase 1 clinical trials. JAMA 292, 2130–2140 (2004).
Mortlock, A. A. et al. Progress in the development of selective inhibitors of aurora kinases. Curr. Top. Med. Chem. 5, 807–821 (2005).
Ruetz, S., Fabbro, D., Zimmermann, J., Meyer, T. & Gray, N. Chemical and biological profile of dual Cdk1 and Cdk2 inhibitors. Curr. Med. Chem. Anti-Canc. Agents 3, 1–14 (2003).
Aghajanian, C. et al. A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. Clin. Cancer Res. 8, 2502–2511 (2002).
Garcia-Manero, G. & Issa, J. P. Histone deacetylase inhibitors: a review of their clinical status as antineoplastic agents. Cancer Invest. 23, 635–642 (2005).
Lahaye, T. et al. Response and resistance in 300 patients with BCR–ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up. Cancer 103, 1659–1669 (2005).
Rinehart, J. et al. Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer. J. Clin. Oncol. 22, 4456–4462 (2004).
Chang, S. M. et al. Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme. Invest. New Drugs 23, 357–361 (2005).
Ellis, L. M. Bevacizumab. Nature Rev. Drug Discov. Suppl. S8–S9 (2005).
Kabbinavar, F. F. et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J. Clin. Oncol. 23, 3697–3705 (2005).
Boye, J., Elter, T. & Engert, A. An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab. Ann. Oncol. 14, 520–535 (2003).
Pegram, M. D. et al. Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer. J. Natl Cancer Inst. 96, 759–769 (2004).
Daub, H., Specht, K. & Ullrich, A. Strategies to overcome resistance to targeted protein kinase inhibitors. Nature Rev. Drug Discov. 3, 1001–1010 (2004).
Litz, J., Sakuntala Warshamana-Greene, G., Sulanke, G., Lipson, K. E. & Krystal, G. W. The multi-targeted kinase inhibitor SU5416 inhibits small cell lung cancer growth and angiogenesis, in part by blocking Kit-mediated VEGF expression. Lung Cancer 46, 283–291 (2004).
Kamb, A. What's wrong with our cancer models? Nature Rev. Drug Discov. 4, 161–165 (2005).
Shah, N. P. & Sawyers, C. L. Mechanisms of resistance to STI571 in Philadelphia chromosome-associated leukemias. Oncogene 22, 7389–7395 (2003).
Yang, J. C. et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N. Engl J. Med. 349, 427–434 (2003).
Jain, R. K., Duda, D. G., Clark, J. W. & Loeffler, J. S. Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nature Clin. Pract. Oncol. 3, 24–40 (2006).
Saund, M. S., Demetri, G. D. & Ashley, S. W. Gastrointestinal stromal tumors (GISTs). Curr. Opin. Gastroenterol. 20, 89–94 (2004).
Muller, A. M. et al. Imatinib mesylate as a novel treatment option for hypereosinophilic syndrome: two case reports and a comprehensive review of the literature. Ann. Hematol. 85, 1–16 (2006).
Gardner, S. N. & Fernandes, M. New tools for cancer chemotherapy: computational assistance for tailoring treatments. Mol. Cancer Ther. 10, 1079–1084 (2003).
Scherf, U. et al. A gene expression database for the molecular pharmacology of cancer. Nature Genet. 24, 236–244 (2000).
Brown, P. et al. Pediatric AML primary samples with FLT3/ITD mutations are preferentially killed by FLT3 inhibition. Blood 104, 1841–1849 (2004).
Kroymann, J. & Mitchell-Olds, T. Epistasis and balanced polymorphism influencing complex trait variation. Nature 5, 95–98 (2005).
Piekarz, R. L. et al. Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report. Blood 98, 2965–2868 (2001).
Dancey, J. E. & Chen, H. X. Strategies for optimizing combinations of molecularly targeted anticancer agents. Nature Rev. Drug Discov. 5, 649–659 (2006).
Tsao, M. S. et al. Erlotinib in lung cancer — molecular and clinical predictors of outcome. N. Engl. J. Med. 353, 133–144 (2005).
Pao, W. & Miller, V. A. Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions. J. Clin. Oncol. 23, 2556–2568 (2005).
Eberhard, D. A. et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J. Clin. Oncol. 23, 5900–5009 (2005).
Talpaz, M. et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N. Engl J. Med. 354, 2531–2241 (2006).
Jonkers, J. & Berns, A. Oncogene addiction: sometimes a temporary slavery. Cancer Cell 6, 535–538 (2004).
Kaelin, W. G. The concept of synthetic lethality in the context of anticancer therapy. Nature Rev. Cancer 5, 689–698 (2005).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
A. Kamb is an employee of Amgen. S. Wee and C. Lengauer are employees of Novartis.
Rights and permissions
About this article
Cite this article
Kamb, A., Wee, S. & Lengauer, C. Why is cancer drug discovery so difficult?. Nat Rev Drug Discov 6, 115–120 (2007). https://doi.org/10.1038/nrd2155
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd2155
This article is cited by
-
Use of patient-derived explants as a preclinical model for precision medicine in colorectal cancer: A scoping review
Langenbeck's Archives of Surgery (2023)
-
Personalization of medical treatments in oncology: time for rethinking the disease concept to improve individual outcomes
EPMA Journal (2021)
-
Role of non-coding RNAs and RNA modifiers in cancer therapy resistance
Molecular Cancer (2020)
-
DRAP: a toolbox for drug response analysis and visualization tailored for preclinical drug testing on patient-derived xenograft models
Journal of Translational Medicine (2019)